Karolinska Institutet (KI), founded in 1810, is Sweden’s only university especially focusing on biomedical sciences. In addition, KI annually awards the Nobel Prize in Physiology or Medicine. KI ranks as one of the world’s leading medical universities; its research activities account for 40% of all medical research in Sweden.
Dr Lehtiö is principal investigator in mass spectrometry based clinical cancer omics. Lehtiö’s research group have significant competence on mass spectrometry based technology research, cell biology, bioinformatics and clinical cancer research. Lehtiö’s group includes 2 assistant professors (Dr Anders Nordström, Metabolomics and Dr Jenny Forshed, Bioinformatics), 3 postdoctoral fellows and 3 PhD students. The group have developed several methods to improve quantitative proteomics (Lengqvist J., et. al. Proteomics 2007; ErikssonH., et al Proteomics 2008; Nordström A., et al Anal Chem. 2008) and utilised them successfully on cancer research (OrreLM., et al MCP 2007; Pernemalm M., et al Proteomics; De Petris L., et al Lung Cancer 2009). Dr Lehtiö is responsible for cutting edge technology platform for mass spectrometry based research including LC-MALDI-TOF/TOF (AB4800, Applied Biosystems), Triple quadrupole MS (Agilent), LC-QTOF (Agilent) and a high resolution MS-instrument with multiple ion sources (nano and capLC- Orbitrap, with ESI, MALDI and API ion sources).
Dr Lehtiö’s group is located at Department of Oncology and Pathology, where instrumentation for tissue microarray preparation as well as microscopes, cell cultivation rooms, FACS for cell analysis as well as modern laboratory facilities. Additionally, Lehtiö’s has been involved in the set-up of the clinical sample collection for lung cancer biobank implementing meticulous standard operation procedure to have high quality clinical samples for omics research.